SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dauntless who wrote (3012)3/25/1998 2:01:00 PM
From: Hank  Read Replies (1) of 7041
 
I don't feel I've been sucked in by anything. I've made my decision based on my experience in this area and the probability that Vasomax will get FDA approval. The issue of patent rejections has never been part of my decision. I know from experience how easy it is to get around a patent rejection with a good patent lawyer. All it takes is a small change in the wording or the formulation itself to make the patent appear as though it represents a "novel" compound. None of this affects the pharmacology of the drug being patented. It says nothing about the probability that Vasomax will receive FDA approval. It only becomes important IF Vasomax is approved. Until I am convinced that Vasomax's chances for FDA approval are better than I believe them to be, I will remain short.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News